LPOXY Therapeutics to Acquire Key Assets from Xeno Biosciences to Advance C. difficile Infection Prevention Therapy

LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced...

January 06, 2025 | Monday | News
Innovent Biologics Receives NMPA Approval for DOVBLERON® (Taletrectinib Adipate) as a Treatment for ROS1-Positive NSCLC

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 03, 2025 | Friday | News
Qualia NAD+ Achieves Clinical Proof for Boosting NAD+ Levels by 67% through Simple Supplementation

 Qualia NAD+, a new supplement by the pioneering Qualia Life Sciences team has now achieved clinical proof that it can boost NAD+ levels through simpl...

January 03, 2025 | Friday | News
SciSparc Secures Renewal to Advance SCI-210 Clinical Trial for Autism Spectrum Disorder

SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, to...

January 02, 2025 | Thursday | News
Corcept Therapeutics Submits NDA to FDA for Relacorilant to Treat Cushing’s Syndrome

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab...

January 02, 2025 | Thursday | News
Innovent Biologics and Roche Partner to Advance Novel DLL3-Targeted ADC for Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 02, 2025 | Thursday | News
BeiGene Exercises Option for DB1312/BG-C9074, Securing Global Rights to DualityBio's B7H4 Antibody-Drug Conjugate

Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...

December 31, 2024 | Tuesday | News
VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Approved by Japan’s MHLW for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...

December 31, 2024 | Tuesday | News
Takeda Receives Japanese Regulatory Approval for HYQVIA® in Primary and Secondary Immunodeficiency Disorders

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...

December 31, 2024 | Tuesday | News
Sangamo Therapeutics Regains Rights to Giroctocogene Fitelparvovec Following Pfizer's Decision to End Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced it will regain development and commercialization rights to giroctocog...

December 31, 2024 | Tuesday | News
Johnson & Johnson Secures EC Approval for Amivantamab-Lazertinib Combo as First-Line Treatment for EGFR-Mutated NSCLC

  Janssen-Cilag International NV, a Johnson & Johnson company,  announced the European Commission (EC) approval of RYBREVANT®▼ (amivan...

December 30, 2024 | Monday | News
IDEAYA Biosciences Acquires Global Rights to SHR-4849 DLL3-Targeting ADC in $1 Billion Agreement with Hengrui Pharma

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...

December 30, 2024 | Monday | News
Japan Approves VYVDURA® for At-Home Self-Injection in gMG and CIDP, Setting a Global Benchmark

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfoli...

December 27, 2024 | Friday | News
AusperBio Therapeutics Secures $73M Series B Funding to Advance Targeted Therapies for Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

December 27, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close